Evidence map›Paper›PMID 33611725›Full record

Trial reportInternational journal of hematology2021

Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.

Seitaro Terakura, Yachiyo Kuwatsuka, Junichi Sugita, Satoshi Takahashi, Yukiyasu Ozawa, Kazutaka Ozeki, Satoshi Yoshioka, Hirohisa Nakamae, Toshiro Kawakita, Masashi Sawa and 11 more

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 1 country.

Seitaro TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, Aichi, 466-8560, Japan. tseit@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0002-1194-8046
Yachiyo KuwatsukaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Junichi SugitaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Satoshi TakahashiDivision of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Kazutaka OzekiDepartment of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan.
Satoshi YoshiokaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka City University Hospital, Osaka, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Satoshi MorishigeDivision of Hematology and Oncology, Department of Medicine, Kurume University Hospital, Kurume, Japan.
Yuho NajimaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Yuna KatsuokaDepartment of Hematology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Yasuji KouzaiDepartment of Transfusion Medicine, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.
Takafumi KimuraPreparation Department, Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Takahiro FukudaDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Makoto MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, Aichi, 466-8560, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Hokkaido University · JPNagoya University Hospital · JPAnjo Kosei Hospital · JPChiba University Hospital · JPHiroshima University · JPJapanese Red Cross Society, Japan · JPKobe City Medical Center General Hospital · JPKonan Kosei Hospital · JPKumamoto Medical Center · JPKurume University Hospital · JPNagoya University · JPOsaka City University Hospital · JPSendai Medical Center · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPThe University of Tokyo · JPTokyo Metropolitan Komagome Hospital · JPTokyo Metropolitan Tama Medical Center · JP

Funding

Japan Society for the Promotion of Science 18k08351
6 · The paper itself

Abstract

To investigate the association between methotrexate (MTX) dosage and engraftment, graft-versus-host disease (GVHD) incidence, and survival in umbilical cord blood transplantation (UCBT), we compared transplant outcomes after UCBT with various GVHD prophylaxis regimens, using registry data with additional data collection. Patients transplanted for acute myeloid leukemia with a calcineurin inhibitor (CNI) and either MTX or mycophenolate mofetil (MMF) combination were selected. In total, 888 single-unit UCBTs (MTX

Indexed as

Cord Blood Stem Cell TransplantationRegistriesAdolescentAdultAllograftsDose-Response Relationship, DrugFemaleGraft vs Host DiseaseHumansJapanLeukemia, Myeloid, AcuteMaleMethotrexateMiddle AgedRetrospective StudiesMethotrexateGraft-versus-host disease (GVHD)GVHD prophylaxisImmunosuppressant selectionMethotrexate doseSingle-unit umbilical cord blood transplantation

Identifiers

PMID33611725
OpenAlexW3129579155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.